Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse
Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.
Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma
An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.
Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety
Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.
Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study
An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.
Biochemical and Clinical Progression: The Two Faces of Relapsed MM
Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.
Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.
Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope
TECing a Closer Look at Teclistamab with Dr. Saad Usmani
This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.
CAR-NKT cells: More of a Goldilocks or a Kangaroo?
The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
Will CAR-T Therapy Replace Transplant in Myeloma and Lymphoma?
2 Clarke Drive Cranbury, NJ 08512